Oncology Brothers: Practice-Changing Cancer Discussions

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial.
 
Join us as we explored:
The evolution of treatment standards for MIBC over the past 2 years
Key insights from the VOLGA trial, including study design, findings, and clinical implications
The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen
The balance between overtreatment and undertreatment in patient care
The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/
 
Don't forget to like, subscribe, and share your thoughts in the comments!
#BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial

We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib.
 
Key topics covered include:
The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma
The shift from single-agent osimertinib to combination therapies and the implications for patient care
Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations
The importance of shared decision-making in oncology
Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression
 
Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion!
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966  
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations.
 
#EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment.
 
Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice:
DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC)
SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy
KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile
PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits
 
Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
 
#LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies.
 
Join us as we discussed:
HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment
CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings
AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery
CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer
HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study
 
Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast!
 
#GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers

In this discussion we dived into the latest breakthroughs in head and neck cancer and melanoma from ESMO 2026. In this episode, we welcomed Dr. Ari Rosenberg from the University of Chicago, to discuss promising data on amivantamab for HPV-negative head and neck cancer, including its efficacy in frontline settings and important considerations for managing side effects. We also had the opportunity to talk to Dr. Sapna Patel from the University of Colorado, who shared insights on the INTerpath-001 study, exploring the role of personalized mRNA vaccines in the adjuvant setting for melanoma.
 
Additionally, we discussed the STARBOARD trial, which investigated the triplet therapy of pembrolizumab, encorafenib, and binimetinib for BRAF V600E/K-positive melanoma patients.
 
Tune in to hear our thoughts on how these findings may change clinical practice and the future of treatment options in oncology.
 
Key Points
Amivantamab shows promising efficacy in HPV-negative head and neck cancer, particularly in the frontline setting, with a manageable toxicity profile that requires proactive side effect management.
Personalized mRNA vaccines in the adjuvant setting for melanoma represent a novel approach, with the INTerpath-001 study comparing this strategy against current standards of care.
The STARBOARD trial evaluates triplet therapy with pembrolizumab, encorafenib, and binimetinib in BRAF V600E/K-positive melanoma, with the potential to change clinical practice.
Logistical challenges, including vaccine manufacturing timelines and treatment coordination, remain important considerations for implementing these emerging therapies.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!
#HeadAndNeckCancer, #Melanoma, #mRNAVaccine, #OncologyBrothers

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by Dr. Sumanta "Monty" Pal, MD, a GU medical oncologist from the City of Hope, for a rapid-fire round discussing key questions from the oncology community about renal cell carcinoma (RCC).
 
Join us as we dived into topics including:
The standard of care for early-stage RCC and the role of adjuvant therapies like pembrolizumab with and without belzutifan
Treatment strategies for oligometastatic disease and the use of radiation
Insights on the use of circulating tumor DNA (ctDNA) in adjuvant settings and the implications of treatment breaks for patients on immuno-oncology (IO)–tyrosine kinase inhibitor (TKI) regimens
The evolving landscape of metastatic RCC, including the comparison of IO-IO versus IO-TKI combinations and the importance of patient-centered decision-making
The challenges and considerations in treating non–clear cell RCC, including the latest data on treatment options
 
Whether you're a healthcare professional or simply interested in the latest advancements in oncology, this episode is packed with valuable insights and expert opinions.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes!
#RCC, #KidneyCancer, #AdjuvantTherapy, #IO-TKI, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Drs. Shilpa Gupta and Ashish Kamat, to discuss the latest updates from ESMO 2026 in Madrid. With nearly 40,000 attendees and thousands of abstracts presented, we focus on the most impactful findings in genitourinary (GU) oncology.
 
Episode Highlights:
Muscle-Invasive Bladder Cancer (MIBC): A deep dive into the VOLGA trial, exploring the efficacy of neoadjuvant therapy with durvalumab and enfortumab vedotin (EV) in MIBC. We discussed the implications of reduced toxicity and potential changes to standard care.
Non-Muscle-Invasive Bladder Cancer (NMIBC): Insights from the POTOMAC update and the role of durvalumab in high-risk, BCG-naive patients.
Prostate Cancer: An overview of the DASL-HiCaP and PROTEUS studies, highlighting the use of androgen receptor pathway inhibitors (ARPIs) in earlier lines of treatment and their impact on metastasis-free survival (MFS).
Renal Cell Carcinoma (RCC): Updates on KEYNOTE-564 and the LITESPARK studies, focusing on adjuvant therapies and the balance between efficacy and side effects.
 
Join us as we cut through the noise and focus on what is practice-changing in the field of oncology.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to subscribe for more insights and updates from the world of cancer research!
 
#ESMO2026, #GUOncology, #BladderCancer, #ProstateCancer, #KidneyCancer, #OncologyBrothers

In this episode of the Oncology Brothers podcast, we dived deep into the complexities of second-line treatment options for multiple myeloma, with a special focus on CAR T-cell therapy. Joined by experts Dr. Rafael Fonseca, a multiple myeloma specialist from the Mayo Clinic; Dr. Beth Faiman, a nurse practitioner specializing in myeloma; and Ms. Carrie Bellerive, a clinical nurse coordinator at Memorial Sloan Kettering Cancer Center, the discussion covers:
 
The eligibility criteria for CAR T-cell therapy and the data supporting its effectiveness
Insights from recent clinical trials, including CARTITUDE-1 and CARTITUDE-2, highlighting long-term outcomes and potential for cure
The importance of patient preparation and shared decision-making in treatment planning
The role of bridging therapy and the significance of managing disease burden prior to CAR T-cell infusion
An overview of acute and chronic side effects associated with CAR T-cell therapy, including cytokine release syndrome (CRS) and neurotoxicity
The critical coordination efforts behind the scenes to ensure seamless patient care
 
Join us as we explore how collaboration among healthcare professionals can enhance patient outcomes in the evolving landscape of multiple myeloma treatment.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
Follow us on social media:
⁠X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
Don't forget to like, subscribe, and share your thoughts in the comments!
#MultipleMyeloma, #CARTtherapy, #BridgingTherapy, #HoldingTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we dived into the world of CAR T-cell therapy, featuring insights from hematology experts Drs. Luciano Costa and Shernan Holtan.
 
Join us as we explore:
The basics of CAR T-cell therapy and the patient journey from referral to infusion
The approved indications for CAR T-cell therapy in multiple myeloma and lymphoma, including the differences between idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel)
The importance of holding and bridging therapies to optimize patient outcomes
The evolving landscape of side effects associated with CAR T-cell therapy, including acute and chronic effects
Strategies for community oncologists to better manage patient care and improve access to CAR T-cell therapies
 
With the potential for curative outcomes in myeloma and lymphoma, understanding these therapies is crucial for both patients and healthcare providers. Tune in for an informative discussion that aims to bridge the gap between community oncology and specialized care.
 
Listen us on:Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o
 
Follow us on social media:•⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes on the latest advancements in cancer treatment!
#CARTtherapy, #MultipleMyeloma, #Lymphoma, #BridgingTherapy, #OncologyBrothers

Welcome to the Oncology Brothers podcast! In this episode, we were joined by Dr. Ronak Mistry, a hematologist from Penn Medicine, for a rapid-fire round addressing common questions about thrombocytopenia.
 
We dived into a variety of topics, including:
Differentiating between inherited thrombocytopenia and mild immune thrombocytopenia (ITP)
The role of steroids and bone marrow biopsy in diagnosis
Management of anticoagulation in patients with low platelet counts
Key distinctions between ITP, atypical hemolytic uremic syndrome (aHUS), and thrombotic thrombocytopenic purpura (TTP)
Recent updates to ITP guidelines and the incorporation of new treatment options
Thrombocytopenia in pregnancy and its management
Treatment options for chemotherapy-induced thrombocytopenia
Common medications that may contribute to thrombocytopenia
 
Join us as we explore these important topics and provide practical insights for healthcare professionals dealing with thrombocytopenia in their clinical practice.
 
Listen us on:
Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o 
 
Follow us on social media:
X/Twitter: https://x.com/oncbrothers 
⁠Instagram: https://www.instagram.com/oncbrothers 
Website: https://oncbrothers.com/ 
 
Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!
#Thrombocytopenia, #ITP, #TTP, #aHUS, #OncologyBrothers